182 related articles for article (PubMed ID: 29520805)
21. Place of cabergoline in acromegaly: a meta-analysis.
Sandret L; Maison P; Chanson P
J Clin Endocrinol Metab; 2011 May; 96(5):1327-35. PubMed ID: 21325455
[TBL] [Abstract][Full Text] [Related]
22. Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice.
Geer EB; Sisco J; Adelman DT; Ludlam WH; Haviv A; Liu S; Mathias SD; Gelbaum D; Shi L
BMC Endocr Disord; 2020 Jul; 20(1):117. PubMed ID: 32736547
[TBL] [Abstract][Full Text] [Related]
23. [Role of somatostatin receptor ligands in the treatment of acromegaly--literature review].
Nemes O; Mezosi E
Orv Hetil; 2011 May; 152(18):715-21. PubMed ID: 21498160
[TBL] [Abstract][Full Text] [Related]
24. Remission of acromegaly after treatment withdrawal in patients controlled by cabergoline alone or in combination with octreotide: results from a multicenter study.
Casagrande A; Bronstein MD; Jallad RS; Mota JI; Tabet A; Abucham J
J Endocrinol Invest; 2017 May; 40(5):523-528. PubMed ID: 28012070
[TBL] [Abstract][Full Text] [Related]
25. Effect of Cabergoline Treatment on Disease Control in Acromegaly Patients.
Hacisahinogullari H; Yalin GY; Selcukbiricik OS; Gul N; Bilgic B; Uzum AK; Tanakol R; Aral F
Horm Metab Res; 2022 Oct; 54(10):664-670. PubMed ID: 36206759
[TBL] [Abstract][Full Text] [Related]
26. Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands.
Fleseriu M; Molitch M; Dreval A; Biermasz NR; Gordon MB; Crosby RD; Ludlam WH; Haviv A; Gilgun-Sherki Y; Mathias SD
Front Endocrinol (Lausanne); 2021; 12():627711. PubMed ID: 33790860
[TBL] [Abstract][Full Text] [Related]
27. Medical treatment of acromegaly-experience from the Croatian acromegaly registry.
Solak M; Kraljević I; Popovac H; Šambula L; Polovina TŠ; Balaško A; Tomšić KZ; Dušek T; Novak A; Tripolski M; Kaštelan D
Endocrine; 2023 Sep; 81(3):555-561. PubMed ID: 37389718
[TBL] [Abstract][Full Text] [Related]
28. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study.
Puig-Domingo M; Soto A; Venegas E; Vilchez R; Blanco C; Cordido F; Lucas T; Marazuela M; Casany R; Cuatrecasas G; Fajardo C; Gálvez MÁ; Maraver S; Martín T; Romero E; Paja M; Picó A; Bernabeu I; Resmini E;
Endocrinol Nutr; 2016 Oct; 63(8):397-408. PubMed ID: 27448708
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of cabergoline in non-irradiated patients with acromegaly: a multi-centre cohort study.
Urwyler SA; Samperi I; Lithgow K; Mavilakandy A; Matheou M; Bradley K; Pal A; Reddy NL; Ay J; Karavitaki N
Eur J Endocrinol; 2024 Jan; ():. PubMed ID: 38231133
[TBL] [Abstract][Full Text] [Related]
30. Cabergoline in the treatment of acromegaly: a study in 64 patients.
Abs R; Verhelst J; Maiter D; Van Acker K; Nobels F; Coolens JL; Mahler C; Beckers A
J Clin Endocrinol Metab; 1998 Feb; 83(2):374-8. PubMed ID: 9467544
[TBL] [Abstract][Full Text] [Related]
31. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.
Cozzi R; Attanasio R; Lodrini S; Lasio G
Clin Endocrinol (Oxf); 2004 Aug; 61(2):209-15. PubMed ID: 15272916
[TBL] [Abstract][Full Text] [Related]
32. Pegvisomant and cabergoline combination therapy in acromegaly.
Bernabeu I; Alvarez-Escolá C; Paniagua AE; Lucas T; Pavón I; Cabezas-Agrícola JM; Casanueva FF; Marazuela M
Pituitary; 2013 Mar; 16(1):101-8. PubMed ID: 22396133
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly.
Selvarajah D; Webster J; Ross R; Newell-Price J
Eur J Endocrinol; 2005 Apr; 152(4):569-74. PubMed ID: 15817912
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study.
Shimon I; Adnan Z; Gorshtein A; Baraf L; Saba Khazen N; Gershinsky M; Pauker Y; Abid A; Niven MJ; Shechner C; Greenman Y
Endocrine; 2018 Nov; 62(2):448-455. PubMed ID: 30051198
[TBL] [Abstract][Full Text] [Related]
35. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: MANAGEMENT OF ACROMEGALY PATIENTS: WHAT IS THE ROLE OF PRE-OPERATIVE MEDICAL THERAPY?
Fleseriu M; Hoffman AR; Katznelson L;
Endocr Pract; 2015 Jun; 21(6):668-73. PubMed ID: 26135961
[TBL] [Abstract][Full Text] [Related]
36. Remission of acromegaly following long-term therapy with cabergoline: report of two cases.
Verhelst JA; Abrams PJ; Abs R
Pituitary; 2008; 11(1):103-7. PubMed ID: 17530416
[TBL] [Abstract][Full Text] [Related]
37. Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly.
Gatto F; Biermasz NR; Feelders RA; Kros JM; Dogan F; van der Lely AJ; Neggers SJ; Lamberts SW; Pereira AM; Ferone D; Hofland LJ
Eur J Endocrinol; 2016 May; 174(5):651-62. PubMed ID: 26888629
[TBL] [Abstract][Full Text] [Related]
38. Cabergoline treatment of acromegaly: a preliminary dose finding study.
Jackson SN; Fowler J; Howlett TA
Clin Endocrinol (Oxf); 1997 Jun; 46(6):745-9. PubMed ID: 9274706
[TBL] [Abstract][Full Text] [Related]
39. IGF-I Variability Over Repeated Measures in Patients With Acromegaly Under Long-Acting Somatostatin Receptor Ligands.
Maione L; Albrici C; Grunenwald S; Mouly C; Cimino V; Lecoq AL; Souberbielle JC; Caron P; Chanson P
J Clin Endocrinol Metab; 2022 Aug; 107(9):e3644-e3653. PubMed ID: 35772775
[TBL] [Abstract][Full Text] [Related]
40. Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trials.
Alquraini H; Del Pilar Schneider M; Mirakhur B; Barkan A
Pituitary; 2018 Jun; 21(3):283-289. PubMed ID: 29357081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
